RITUXIMAB in Lupus Related Autoimmune Haemolytic Anemia

The treatment of choice of warm antibody Autoimmune Hemolytic Anemia is still corticosteroids. While many centres have now adopted rituximab as the 2nd line agent over splenectomy, there is also data on upfront use of rituximab in Autoimmune Hemolytic Anemia / Idiopathic Thrombocytopenic Purpura. We report a case for the role of Rituximab in a patient of adult autoimmune haemolytic anaemia who was refractory to the conventional corticosteroid therapy. We have used rituximab early on in our patient with good response.